About Us
Research & Development
Vascular Integrity
- Adrenomedullin
- Sepsis & Septic Shock
News & Events
Contact

About Us
Research & Development
Vascular Integrity
- Adrenomedullin
- Sepsis & Septic Shock
News & Events
Contact

Article in ENDPOINTS: Wellington, HBM lead €24M round as Adrenomed preps septic shock treatment for human testing

27. November 2018

by Amber Tong.

Go to the article

Search for:

Adrenomed AG announces publication of Phase II trial design of Adrecizumab to treat septic shock

7. February 2019

International Opinion Leaders Align on Value of Adrenomedullin as Therapeutical Target and Biomarker in Sepsis and Acute Heart Failure

19. December 2018

Adrenomed closes € 24 M financing led by Wellington and HBM

26. November 2018

Adrenomed AG reveals Adrecizumab mode of action

14. June 2018

Clinical Phase II started: Adrenomed doses first patient in proof-of-concept study with Adrecizumab

11. December 2017

Researchers to Present New Preclinical and Clinical Data on Lead Candidate Adrecizumab at Upcoming ESICM (European Society of Intensive Care Medicine) Conference

25. September 2017

More News

Media Coverage

Article in MedNous: Adrenomed – a new approach for treating sepsis

21. January 2019

Article in ENDPOINTS: Wellington, HBM lead €24M round as Adrenomed preps septic shock treatment for human testing

27. November 2018

Recent Events

ISICEM, 39th International Symposium on Intensive Care and Emergency Medicine, March 19.-22, 2019 Brussels, Belgium

30. November 2018

JPM Healthcare Conference, San Francisco, 7.-10.01.2019

30. November 2018

More Events

CONTACT

Contact Info

+49 (0) 3302 20 77 8 0
+49 (0) 3302 20 77 8 15
info@adrenomed.com

ADRENOMED AG

Neuendorfstraße 15A
Hennigsdorf b. Berlin
D-16761, Germany.

Twitter Linkedin

Name

Subject

Message

I agree to the usage and processing of my personal data

Article in ENDPOINTS: Wellington, HBM lead €24M round as Adrenomed preps septic shock treatment for human testing

Recent News

Adrenomed AG announces publication of Phase II trial design of Adrecizumab to treat septic shock

International Opinion Leaders Align on Value of Adrenomedullin as Therapeutical Target and Biomarker in Sepsis and Acute Heart Failure

Adrenomed closes € 24 M financing led by Wellington and HBM

Adrenomed AG reveals Adrecizumab mode of action

Clinical Phase II started: Adrenomed doses first patient in proof-of-concept study with Adrecizumab

Researchers to Present New Preclinical and Clinical Data on Lead Candidate Adrecizumab at Upcoming ESICM (European Society of Intensive Care Medicine) Conference

Media Coverage

Article in MedNous: Adrenomed – a new approach for treating sepsis

Article in ENDPOINTS: Wellington, HBM lead €24M round as Adrenomed preps septic shock treatment for human testing

Recent Events

ISICEM, 39th International Symposium on Intensive Care and Emergency Medicine, March 19.-22, 2019 Brussels, Belgium

JPM Healthcare Conference, San Francisco, 7.-10.01.2019

Archive

CONTACT

Contact Info